You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 601 - 625 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma Trial (Sintilimab)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Jan 12, 2022

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Meningioma, Malignant Trial in Beijing (Sintilimab)

Recruiting
  • Meningioma, Malignant
  • Beijing, Beijing, China
    Beijing TianTan Hospital
Aug 9, 2021

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Cervical Cancer Trial in Nanning (tislelizumab, concurrent chemoradiotherapy)

Not yet recruiting
  • Cervical Cancer
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 22, 2022

Recurrent Glioblastoma Multiforme(GBM) Trial in Houston (ACT001, ACT001 + Pembrolizumab)

Recruiting
  • Recurrent Glioblastoma Multiforme(GBM)
  • Houston, Texas
    UT MD Anderson Cancer Center, Dept of Neuro-Oncology
Nov 12, 2021

Solid Tumor Trial (JAB-BX102 (anti-CD73 mAb), pembrolizumab (anti-PD-1 mAb))

Not yet recruiting
  • Solid Tumor
  • JAB-BX102 (anti-CD73 monoclonal antibody)
  • pembrolizumab (anti-PD-1 monoclonal antibody)
  • (no location specified)
Jul 19, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

Not yet recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 28, 2023

Ovarian Cancer Trial (AK104 - Chemotherapy)

Not yet recruiting
  • Ovarian Cancer
  • AK104 - Chemotherapy
  • (no location specified)
Jun 20, 2022

PraG With RANKL Inhibitor for Treatment of Advanced Multiple

Not yet recruiting
  • Metastatic Solid Tumor
  • Suzhou, Jiangsu, China
    The Second Affiliated Hospital of Soochow University
Aug 16, 2022

Carcinoma, Solid Tumor Trial in China (ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
  • Changchun, China
  • +18 more
Nov 4, 2021

Progress Free Survival (PFS) and Overall Survival (OS) Trial in Guangzhou (Bevacizumab Injection, Nivolumab)

Completed
  • Progress Free Survival (PFS) and Overall Survival (OS)
  • Guangzhou, Guangdong, China
    Fuda Cnacer Hospital
Sep 1, 2021

Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
  • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Jan 22, 2023

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

Recruiting
  • Recurrent Endometrial Cancer
  • Solid Tumors
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 12, 2022

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Pancreatic Cancer Trial in Hangzhou (Anti-PD-1 mAb)

Recruiting
  • Pancreatic Cancer
  • Anti-PD-1 monoclonal antibody
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Jul 18, 2021

Advanced Solid Tumor Trial in United States (AGEN1571, Balstilimab, Botensilimab)

Recruiting
  • Advanced Solid Tumor
  • Los Angeles, California
  • +4 more
Jan 17, 2023

Gynecologic Cancer, Cancer Metastatic, Ovarian Tumors Trial in Qilu, Chongqing (AK112)

Active, not recruiting
  • Gynecologic Cancer
  • +4 more
  • Qilu, Shandong, China
  • +1 more
Oct 8, 2022

Esophageal Squamous Cell Carcinoma Trial in Suzhou (Sintilimab + chemo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Sintilimab + chemotherapy
  • Suzhou, Jiangsu, China
    The first affiliated hospital of soochow university
Dec 13, 2021

Adverse Myocardial and Vascular Side Effects of Immune

Active, not recruiting
  • Cancer
  • +2 more
  • Cardiac MRI
  • +2 more
  • Paris, France
    AP-HP - Hôpital européen Georges-Pompidou
May 2, 2022

Advanced or Metastatic Solid Tumors Trial (HLX60 combined with HLX10)

Not yet recruiting
  • Advanced or Metastatic Solid Tumors
  • HLX60 combined with HLX10
  • (no location specified)
Aug 1, 2022

Metastatic Renal Cell Cancer Trial in United States (Axitinib)

Active, not recruiting
Has Results
  • Metastatic Renal Cell Cancer
  • Duarte, California
  • +3 more
Jun 1, 2022

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Brain Cancer Trial in United States (MK-3475)

Completed
  • Brain Cancer
  • Los Angeles, California
  • +6 more
Jun 6, 2022